MétaCan
Menu
Back to cohort
Record W4391693325 · doi:10.1016/j.cjco.2024.01.013

Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial

2024· article· en· W4391693325 on OpenAlexaff
Ayodele Odutayo, Bernard Zinman, Christoph Wanner, Isabella Zwiener, Søren S. Lund, Stefan Hantel, David Fitchett, Jacob A. Udell

Bibliographic record

VenueCJC Open · 2024
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsSt. Michael's HospitalLunenfeld-Tanenbaum Research InstituteMount Sinai HospitalWomen's College HospitalUniversity of TorontoUniversity Health Network
FundersBoehringer IngelheimEli Lilly and Company
KeywordsEmpagliflozinMedicineHazard ratioInternal medicineMyocardial infarctionCardiologyStroke (engine)Coronary artery diseaseDiabetes mellitusType 2 Diabetes MellitusPlaceboType 2 diabetesConfidence intervalEndocrinologyPathology

Abstract

fetched live from OpenAlex

BackgroundIn patients with type 2 diabetes mellitus (T2DM), a history of an ischemic event is associated with increased risk for cardiovascular disease. Whether patients with T2DM and a recent atherothrombotic diagnosis benefit from early intervention with a sodium-glucose co-transporter 2 (SGLT2) inhibitor is unknown.MethodsThis is a secondary analysis of EMPA-REG OUTCOME, which compared empagliflozin to placebo in adults with T2DM and atherosclerotic cardiovascular disease (ASCVD). Participants were categorized based on the time since their last qualifying ASCVD diagnosis (≤1 year versus >1 year). Qualifying ASCVD diagnoses included ischemic or hemorrhagic stroke, myocardial infarction (MI), coronary artery disease, or peripheral artery disease. The primary outcome was a composite of cardiovascular death, non-fatal MI, or non-fatal stroke.Results6,796 participants (n=4,547 empagliflozin, n=2,249 placebo) were included. Median time since the last qualifying ASCVD diagnosis was 3.8 years (Quartile1–Quartile3: 1.5–7.6), and most qualifying diagnoses occurred >1 year before randomization (≤1 year: n=1,214, >1 year n=5,582). Empagliflozin reduced the primary outcome irrespective of the time since the last qualifying ASCVD diagnosis (≤1 year: hazard ratio [HR] 0.82, 95% confidence interval [CI]: 0.57–1.16; versus >1 year : HR 0.85, 95%-CI: 0.72–1.00; p-interaction=0.84). Results were similar for the composite of cardiovascular death or hospitalization for heart failure.ConclusionsEmpagliflozin improved cardiovascular outcomes in participants with T2DM, irrespective of the time since the last qualifying ASCVD diagnosis at randomization. Prospective trials are necessary to investigate the use of SGLT2 inhibitors at the time of an acute ASCVD event.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.359
Threshold uncertainty score0.528

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.319
Teacher spread0.280 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCJC OpenSame topicDiabetes Treatment and ManagementFrench-language works237,207